19.01.2011 • News

Amgen To Sell California Drug Plant To Boehringer

Amgen, the world's biggest maker of biotechnology drugs, plans to sell its Fremont, Calif., development and manufacturing plant to Germany's Boehringer Ingelheim, the companies said on Tuesday. Financial terms were not disclosed.

Amgen, based in Thousand Oaks, Calif., said the 100,000-square-foot plant employs about 360 people who will become employees of Boehringer.

The German company, which has manufactured Amgen drugs on a contract basis for more than 10 years, said the deal will allow it to expand contract manufacturing, process development and development of active ingredients based on biologics.

The deal is expected to close in March.

Amgen obtained the Fremont facility in its 2006 acquisition of antibody drug maker Abgenix.

Innovation Pitch

The Start-up Platform for Chemistry & Life Sciences
Discover Tomorrow’s Innovators

The Start-up Platform for Chemistry & Life Sciences

CHEManager Innovation Pitch supports innovation in the chemistry and life sciences start-up scene. The platform allows founders, young entrepreneurs, and start-ups to present their companies to the industry.

Interview

Leading Transformation
The Path to Sustainable Growth

Leading Transformation

As Executive Vice President of International Chemicals since early 2024, Antje Gerber has been steering Sasol through a pivotal reset—focused on resilience, innovation, and bold sustainability goals.

most read

Photo

VCI Welcomes US-EU Customs Deal

The German Chemical Industry Association (VCI) welcomes the fact that Ursula von der Leyen, President of the European Commission, and US President Donald Trump have averted the danger of a trade war for the time being.